Top Markets
#1 Galxe Galxe +86.35%
#2 Gravity Gravity +67.36%
#3 Akedo Akedo +66.92%
#4 Railgun Railgun +39.44%
#5 Bedrock Bedrock +37.89%
#6 Pearl Pearl +36.88%
#7 TENDIES TENDIES +35.93%
#8 Starknet Starknet +32.02%
#9 MYX Finance MYX Finance +30.01%
#10 Pieverse Pieverse +27.64%
Coin of the day
Galxe Galxe
Settings
Language
ENGLISH
Currency
USD
Theme
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVXA
Rank in Stocks #38483
Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc... Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc operates as a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market innovative therapies for various female sexual dysfunctions. Its primary drug candidate, BP-101, is being developed as a medical treatment for premenopausal women diagnosed with hypoactive sexual desire disorder. This compound is presently in Phase II clinical investigation in Australia and New Zealand, and has progressed to Phase III clinical trials within Russia. Beyond its core pharmaceutical work, the company also participates in mineral exploration and offers supplementary support services. The organization, originally incorporated as Ovoca Gold plc, rebranded to Ovoca Bio plc in July 2018.
Share Price
$0.01142111
Last synced: 2025-03-21
Market Cap
$930.66K
Change (1 day)
0.18%
Change (1 year)
-69.73%
Country
IE
Trade Ovoca Bio plc (OVXA)

Category

Healthcare
Number of shares outstanding for Ovoca Bio plc (OVXA)
Number of shares outstanding as of June 2024: 92.84M
According to Ovoca Bio plc latest financial reports and stock price the company's current number of shares outstanding is 92.84M. At the end of December 2023 the company had 75.11M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Ovoca Bio plc (OVXA) from 2001 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 92.84M -99.55%
2024 20.72B 27,488.06%
2023 75.11M -7.91%
2022 81.56M 0.00%
2021 81.56M 0.00%
2020 81.56M 0.00%
2019 81.56M 0.00%
2018 81.56M 0.00%
2017 81.56M 0.00%
2016 81.56M 0.00%
2015 81.56M -6.64%
2014 87.36M 0.00%
2013 87.36M 0.00%
2012 87.36M -0.61%
2011 87.90M -0.64%
2010 88.46M 0.00%
2009 88.46M 1.33%
2008 87.30M 28.36%
2007 68.01M 45.51%
2006 46.74M 129.03%
2005 20.41M 194.39%
2004 6.93M 19.17%
2003 5.82M 1.55%
2002 5.73M 3.94%
2001 5.51M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 173.50%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -33.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 326.56%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 415.87%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH